Vanguard Group Inc. Sells 60,923 Shares of TransMedics Group, Inc. $TMDX

Key Points

• Vanguard Group Inc. has reduced its stake in TransMedics Group, Inc. by 1.7% during the first quarter, owning approximately 10.57% of the company valued at $240.5 million.
• Insider trading activity includes sales by directors David Weill and Edward M. Basile, who sold shares valued at $90,680 and $632,250 respectively, representing significant decreases in their ownership.
• TransMedics Group reported earnings that exceeded analysts' expectations, with a revenue increase of 37.7% year-over-year, highlighting strong performance in their medical technology sector.

Vanguard Group Inc. cut its holdings in shares of TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) by 1.7% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,574,996 shares of the company's stock after selling 60,923 shares during the period. Vanguard Group Inc. owned about 10.57% of TransMedics Group worth $240,526,000 at the end of the most recent quarter.

Several other institutional investors have also recently bought and sold shares of the business. PNC Financial Services Group Inc. boosted its stake in TransMedics Group by 13.8% in the first quarter. PNC Financial Services Group Inc. now owns 2,294 shares of the company's stock worth $154,000 after purchasing an additional 278 shares in the last quarter. XTX Topco Ltd bought a new position in shares of TransMedics Group in the first quarter valued at about $1,301,000. HB Wealth Management LLC raised its holdings in shares of TransMedics Group by 30.4% in the first quarter. HB Wealth Management LLC now owns 10,627 shares of the company's stock valued at $715,000 after buying an additional 2,478 shares during the last quarter. Tempus Wealth Planning LLC lifted its position in TransMedics Group by 9.2% during the 1st quarter. Tempus Wealth Planning LLC now owns 6,058 shares of the company's stock worth $408,000 after buying an additional 508 shares in the last quarter. Finally, Legato Capital Management LLC bought a new stake in TransMedics Group during the 1st quarter worth about $332,000. Institutional investors own 99.67% of the company's stock.

Insider Transactions at TransMedics Group

In other TransMedics Group news, insider Anil P. Ranganath sold 686 shares of the company's stock in a transaction that occurred on Monday, June 9th. The shares were sold at an average price of $139.80, for a total value of $95,902.80. Following the completion of the sale, the insider owned 13,955 shares of the company's stock, valued at approximately $1,950,909. This represents a 4.69% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Edward M. Basile sold 5,000 shares of the stock in a transaction on Tuesday, May 27th. The stock was sold at an average price of $126.45, for a total transaction of $632,250.00. Following the completion of the sale, the director owned 2,866 shares in the company, valued at approximately $362,405.70. This trade represents a 63.56% decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 7.00% of the company's stock.

Analysts Set New Price Targets

Several equities research analysts have weighed in on the stock. Needham & Company LLC restated a "hold" rating on shares of TransMedics Group in a research report on Tuesday, June 17th. Canaccord Genuity Group increased their price target on shares of TransMedics Group from $129.00 to $142.00 and gave the company a "buy" rating in a research note on Tuesday, July 15th. Morgan Stanley raised their price target on shares of TransMedics Group from $115.00 to $123.00 and gave the company an "equal weight" rating in a report on Friday, August 1st. Wall Street Zen raised TransMedics Group from a "hold" rating to a "buy" rating in a report on Saturday, August 2nd. Finally, Piper Sandler reiterated an "overweight" rating and issued a $145.00 price objective (up from $125.00) on shares of TransMedics Group in a research report on Wednesday, June 4th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and three have issued a Hold rating to the company's stock. According to MarketBeat.com, TransMedics Group presently has a consensus rating of "Moderate Buy" and a consensus price target of $123.00.

TransMedics Group Trading Up 0.9%

Shares of NASDAQ:TMDX traded up $1.04 during midday trading on Friday, hitting $119.85. The company had a trading volume of 1,032,110 shares, compared to its average volume of 1,241,494. TransMedics Group, Inc. has a 12 month low of $55.00 and a 12 month high of $177.37. The company has a current ratio of 9.86, a quick ratio of 9.17 and a debt-to-equity ratio of 1.61. The stock has a market cap of $4.09 billion, a price-to-earnings ratio of 62.10 and a beta of 2.09. The firm has a fifty day simple moving average of $121.65 and a 200 day simple moving average of $101.51.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last released its quarterly earnings data on Wednesday, July 30th. The company reported $0.92 EPS for the quarter, beating analysts' consensus estimates of $0.48 by $0.44. TransMedics Group had a return on equity of 28.02% and a net margin of 13.49%.The business had revenue of $157.37 million during the quarter, compared to the consensus estimate of $146.64 million. During the same quarter in the prior year, the company posted $0.35 earnings per share. The firm's revenue was up 37.7% on a year-over-year basis. TransMedics Group has set its FY 2025 guidance at EPS. On average, analysts predict that TransMedics Group, Inc. will post 1 EPS for the current year.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.